Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The use of methylphenidate in children and adolescents in France from 2010 to 2015
To describe the use of methylphenidate in children and adolescents in France from 2010 to 2015
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| users of methylphenidate | Children and adolescents who are users of methylphenidate, 2010 to 2015 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| users of methylphenidate | Other | Children and adolescents who are users of methylphenidate, 2010 to 2015 |
|
| Measure | Description | Time Frame |
|---|---|---|
| use of methylphenidate over time | Describe of the use of methylphenidate over time to determine the impact of regulatory information of appropriate prescription conditions of use in September 2012 | 6 years |
| Measure | Description | Time Frame |
|---|---|---|
| Describe methylphenidate patterns of use over time | Pharmaceutical specialties (immediate or extended release forms) prescribed by type of delivery: initial or renewals. Profile of prescribers: hospital or private practice (general practitioners, specialists) depending on type of prescription (initial or renewal); geographical distribution of the prescribers Profile of patients: sex, average age and age classes (0-23 months, 2-5 years, 6-11 years, 12-17 years), socioeconomic status, long-lasting diseases status for psychosis, severe personality disorder, mental retardation. Pattern of methylphenidate use: duration of treatment, prolonged use, interruption of treatment. |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Children and adolesents who are users of methylphenidate
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Florentia Kaguelidou, MD, PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Robert Debré, APHP | Paris | 75019 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 years |
| Co-prescription of methylphenidate and non-psychostimulant psychotropic drugs | 6 years |